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Abstract 
The importance of atherosclerosis is driving research to create improved diagnostic 
tools based on molecular imaging. Pretargeted imaging is the use of bioorthogonal 
probes that selectively accumulate upon reaction with a pre-modified biomolecule in 
vivo. To date, this very promising approach has not been applied to atherosclerosis. 
Neither has been the use of a single nano-radiomaterial for PET / T1-MR imaging of 
atherosclerosis. Here, we synthesized bioorthogonal nano-radiomaterials for in vivo 
pretargeted molecular imaging in a mouse model of atherosclerosis. Based on tetrazine-
ligation, these functionalized 68Ga iron oxide nano-radiomaterials provide simultaneous 
PET and T1-MRI signals and selectively accumulate in atherosclerotic plaques in mice 
sequentially injected with trans-cyclooctene-modified antibodies against oxidized LDL 
followed by the hybrid nano-radiomaterial. Our results demonstrate the ability of this 
approach to unambiguously detect atherosclerosis. Furthermore, we show the first 
example of how hybrid imaging can be used for pretargeted bioorthogonal molecular 
imaging with nanomaterials. 
 
 
Keywords: Nano-radiomaterials, atherosclerosis, molecular imaging, iron oxide, 
gallium-68 
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Background 
 
Atherosclerosis is a complex chronic inflammatory disease of the blood vessel wall in 
which plaques build up inside the arteries. The generation of oxidized low-density 
lipoprotein (oxLDL) plays a key role in the initiation, progression and destabilization of 
atherosclerotic lesions.1 OxLDL has therefore been widely used as a target for 
molecular imaging of atherosclerosis. OxLDL is an important target not only due to its 
role in plaque pathobiology, but also because it is a possible marker of plaque 
vulnerability. Molecular imaging studies have focused on antibody-labeled magnetic 
resonance contrasts2,3 and more recently on fluorescence.4,5 In the field of nuclear 
imaging, there are a few examples of single-photon emission computed tomography 
(SPECT) 6–8 and a recent study using positron emission tomography.9 The methodology 
in all these studies share the need to match the lengthy biodistribution of the different 
antibodies in vivo by using long half-life isotopes, such as 125I (t1/2 = 59 days) or 
64Cu 
(t1/2 = 16 hours). 
The development of probes for hybrid molecular imaging is particularly appealing for 
the early diagnosis and characterization of complex diseases like atherosclerosis. The 
combined use of positron emission tomography (PET) and magnetic resonance imaging 
(MRI) technology can provide combined structural and functional information, and this 
approach is beginning to show its potential, particularly in the cardiovascular area.10,11 
There is a growing number of contributions where atherosclerosis is characterized by 
hybrid PET/MR imaging. This is normally done by using a PET radiotracer and, after 
radioactive decay, carrying out the MRI experiments without any contrast agent,12–14 or 
by separated PET and T2-weigthed MRI experiments by the consecutive injection of 
two different probes,15 or one surface-functionalized probe.16 To our knowledge, the 
characterization of atherosclerosis with one probe for hybrid PET/T1-MRI, in one 
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experiment, has not been done before. We recently developed a new kind of nano-
radiomaterial in which short half-life 68Ga isotopes are incorporated in the core of 
extremely small iron oxide particles, combining the size-dependent properties of 
nanotechnology with the unparalleled sensitivity of nuclear imaging techniques. This 
nano-radiomaterial (NRM) provides simultaneous signals for PET and T1-MRI.
17,18 
Bioorthogonal chemistry enables the selective conjugation of two compounds in the 
challenging in vivo environment. Since the ground-breaking work that initiated the use 
of this type of chemistry for biomedical applications, the field has expanded 
tremendously.19–21 
Bioorthogonal or pretargeted molecular imaging is based on the complementary 
labelling of the biomolecule (typically an antibody) and the probe; after injection of the 
biomolecule, the tracer is administered and selectively accumulates at the site of the 
bioorthogonal reaction. This type of chemistry has many advantages in molecular 
imaging and is particularly appealing since it allows the use of short half-life isotopes to 
detect biomolecules with long biodistribution times.22–24 This approach has already been 
applied to the characterization of cancer, using small chelators such as tracers,25–27 
antibodies,28 or nanoparticles.29–31 Among reactions showing bioorthogonal features, 
tetrazine ligation is probably the best suited for in vivo imaging. The extremely rapid 
reaction between trans-cyclooctene (TCO) and tetrazine (TZ) derivatives and the 
variety of compounds available make this reaction the first choice for many applications. 
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Methods 
Antibody functionalization with trans- cyclooctene (Ab-TCO). E-06 antibody (200 g) is 
added to an Eppendorf tube and volume adjusted with PBS 1X to a final volume of 0.5 
ml. The pH of the solution was adjusted to 8.9-9.1 with 90 µl of Na2CO3 0.1 M. Then, 
10 µl of TCO-NHS (1 mg·ml
-1
) were added and the reaction was kept at room 
temperature for 60 min in the vortex. Afterwards, the reaction was purified by ultra-
filtration through 100 KDa cut off filters and dissolved in PBS 1X to reach 0.5 ml. 
 
Synthesis of 
68
Ga-NRM. FeCl3 x 6 H2O (75 mg, 0.28 mmol), citric acid trisodium salt 
(80 mg, 0.27 mmol) and 1280 MBq of 
68
GaCl3 in HCl (0.05 M, 4 mL) were dissolved in 
water (5 mL) in a microwave-adapted flask, followed by addition of hydrazine hydrate 
(55%, 1 mL). The solution was ramped to 100°C over 54 s and held at this temperature 
for 10 minutes (240 W) in a Monowave 300 microwave reactor equipped with an 
internal temperature probe and an external IR probe (Anton Paar, GmbH73760, 
Ostfildern-Scharnhausen, Germany). The reaction mixture was then cooled to 60°C and 
the 
68
Ga-NRM product was purified by passing the mixture through a PD-10 column to 
eliminate excess small reagents, including all unincorporated radiotracer. This 
purification process provided 9 mL of 
68
Ga-NRM with a total activity of 781 MBq 
(measured 40 minutes after starting the reaction), a radiolabeling yield of 92%. 
 
Synthesis of 
68
Ga-NRM-TZ. To 650 MBq of 
68
Ga-NRM (2.25 mL) were added 0.07 
mmol of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) and 
0.075 mmol of N-hydroxysulfosuccinimide sodium salt (Sulfo-NHS). The solution was 
stirred for 30 min at room temperature (r.t.) and then ultracentrifuged at 10350 x g 
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through Amicon 30 kDa centrifugal filters for 4 min to remove excess reagents. The 
nanoparticles were resuspended in 1.5 mL of HEPES buffer 0.5 M, pH = 8, and 1 mg of 
Benzylamino tetrazine hydrochloride dissolved in 50 µL DMSO was added to the 
solution. The mixture was maintained at r.T. for 60 min with stirring. Finally, another 
ultrafiltration step was performed to eliminate unreacted tetrazine. The nanoparticles 
were resuspended in saline solution, yielding 188 MBq (Measured 120 minutes after 
starting reaction) of 
68
Ga-NRM-TZ, a radiolabeling yield of 98.9%. 
 
Analysis of serum. Blood samples were centrifuged at 10350 x g at 4ºC for 7 minutes to 
separate the serum for analysis. 
 
Quantification TCO in Ab. To calculate the amount of TCO in E-06 Antibody after 
conjugation, reaction with fluorescent probe Cy3 Tetrazine (Click chemistry tools) was 
used. First, calibration curve was made at different concentrations of Cy3 Tetrazine: 
100, 50, 10, 8, 6, 4, 2, 0.5 and 0.1 µM. Fluorescence signal was measured at λ = 570 
nm. Then, 0.055 nmoles (50 µg) of the conjugate antibody-TCO dissolved in 100 µL of 
normal saline were mixed with Cy3-Tetrazine to give a final concentration of 200 µM. 
The final solution was vortexed for 2 hours at r.t. Afterwards, sample was purified by 
ultrafiltration with Amicon® 100K. Final product was resuspended in saline solution 
and the fluorescence signal was measured at λ = 570 nm.  
 
Quantification TZ in 
68
Ga-NRM-TZ. To calculate the amount of TZ per NRM after 
conjugation, fluorescent probe Cy5 TCO (Click chemistry tools) was used. To start 
with, a calibration curve was worked out measuring fluorescence signal of different 
TCO Cy5 concentrations (50, 10, 8, 6, 4, 2, 0.5 and 0.1 µM) at λ = 725 nm. Then, 250 
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µl (0.858 mg·ml
-1 
Fe) of 
68
Ga-NRM-TZ dissolved in saline solution were mixed with 
Cy5 TCO to reach a final concentration of 300 µM. Resulting solution was vortexed for 
6 hours at r.t. Once this step was completed, sample was purified by ultrafiltration with 
Amicon® 100K. Final product was resuspended in saline solution and fluorescence 
signal measured at λ = 725 nm. 
In vitro bioorthogonal reaction. Ox-Phospholipid Snooper was first blocked using 10 
mL TBS + 3% BSA for 1 hour at room temperature under gentle shaking. Once this 
step was completed, blocking solution was removed and 2 g of Ab-TCO were added to 
the membrane in 10 mL TBS + 1% BSA and incubated for 1 hour at room temperature 
under gentle shaking. After this, antibody solution was discarded and membrane was 
washed three times with TBS + 3% BSA for 10 minutes. 200l of NRM-TZ were added 
in 10 ml TBS + 1% BSA and incubated at room temperature for 1 hour under gentle 
shaking. After this, solution was discarded and membrane was washed three times with 
TBS + 3% BSA for 10 minutes. NRM accumulation was studied by naked-eye. 
Animals and ethics. All animal experiments conducted in this work were approved by 
the ethics and animal welfare committee at CNIC and were developed according to the 
Spanish and UE legislation. Experimental protocol approved by Madrid regional 
government, PROEX 277/16. 
 
Results  
Synthesis and characterization of the nano-radiomaterial. 
The general hybrid approach followed in this study is summarized in Figure 1. We first 
covalently attached the TCO moiety to E-06, a naturally occurring mouse monoclonal 
IgM antibody (Ab) targeting oxidized LDL, oxidized HDL, and proteins covalently 
modified by oxidized phospholipids. The pentameric structure of the E-06 Ab presents 
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plenty of accessible lysines to attach TCO (highlighted in blue in the IgM structure 
(Figure 1a). TCO is one of the most used molecules for bioorthogonal reactions because 
of its rapid reaction rate with TZ derivatives. The Ab was reacted with TCO N-
hydroxisuccinimidyl ester and purified by ultrafiltration.  
We quantified the number of TCO molecules per Ab by reacting the Ab-TCO with 
fluorescently tagged tetrazine (TZ-Cy3). After the in vitro bioorthogonal reaction and 
purification, the Ab showed quite a strong fluorescent signal (Figure 2a), indicating 
successful tetrazine ligation. Using this signal, we determined that approximately 48 
TCO molecules were bound per Ab molecule (Figure S1), which is optimum for this 
type of in vivo chemistry
32
. In the second step, we synthesized a new 
68
Ga-based nano-
radiomaterial (
68
Ga-NRM). We recently demonstrated the use of this hybrid nano-
radiotracer for PET / MR tumor characterization in vivo,
17
 and for the in vivo detection 
of neutrophils.
18
. Here, we produced a modified version, replacing the dextran coating 
with citrate molecules. The core consists of extremely small iron oxide nanoparticles 
doped with 
68
Ga. NRM synthesis was carried out very rapidly in a microwave oven,
18
 
taking only 15 minutes to obtain the pure, ready-to-use sample. 
68
Ga-NRM were 
purified by gel filtration.  
Radioactive elution profile shows a large peak due to the 
68
Ga incorporated in the core 
of the particles and a small peak due to free 
68
Ga (Figure 2b). We next incorporated the 
tetrazine moiety to the 
68
Ga-NRM surface through amide formation between 
benzylamino-tetrazine and the carboxylic acid groups in citrate (
68
Ga-NRM-TZ, Figure 
1b). Radioactive labelling stability was confirmed by incubation with mouse serum at 
37ºC and then ultrafiltration. Data indicates that all the activity remains within the 
NRM, both for 
68
Ga-NRM and 
68
Ga-NRM-TZ, with no measurable activity in the 
filtrate (Figure 2c). Radiochemical purity of 
68
Ga-NMR-TZ was also confirmed by size 
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exclusion HPLC analysis (Figure S2) showing the same elution time for the radioactive 
signal and the UV channel with absence of radioactive signal for free 
68
Ga
3+
. The FTIR 
spectrum for unmodified 
68
Ga-NRM showed the typical bands for citrate-coated iron 
oxide nanomaterials at 1551 cm
-1
, 1374 cm
-1
, and 1073 cm
-1
 (Figure 2d). After tetrazine 
conjugation, the 
68
Ga-NRM-TZ spectrum showed 2 new bands due to the tetrazine ring, 
at 1156 cm
-1
 and 1030 cm
-1
.
33
 Further analysis by zeta potential measurements showed 
that tetrazine incorporation changed the surface charge from a mean value of -33 mV 
for 
68
Ga-NRM to -25 mV for 
68
Ga-NRM-TZ (N=3) due to the reduction in the number 
of free carboxylate groups (Figure 2e). 
We next tested the presence and reactivity of TZ on the surface of the modified 
68
Ga-
NRM by in vitro bioorthogonal reaction with a commercial dye-labelled TCO (TCO-
Cy5). This allowed us to confirm successful TZ conjugation and reactivity and to 
quantify the amount of conjugated TZ in the 
68
Ga-NRM-TZ. The fluorescence spectrum 
after purification clearly shows the fluorescence signal from the Cy5 dye, whereas there 
is no signal from the initial 
68
Ga-NRM-TZ used as control for the in vitro bioorthogonal 
incubation (Figure 2f, Figure S3). 
To optimize TZ incorporation, we tested 4 benzylamino-tetrazine concentrations in the 
amidation reaction, quantifying amount of incorporated TZ in each reaction from the 
fluorescent signal (Figure 2g). TZ saturation was obtained with the addition of 15 µmol 
of benzylamino-tetrazine. We wanted a nano-radiomaterial able to undergo the 
bioorthogonal reaction while maintaining as far as possible the physicochemical 
properties of the original 
68
Ga-NRM, and therefore selected reaction conditions 
resulting in a tracer incorporating 675 nmol of TZ per mmol Fe (Figure 1b).  
To evaluate the colloidal properties of the samples we measured hydrodynamic size by 
dynamic light scattering. Hydrodynamic size was similar and extremely low in both 
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samples, measuring 14.7 ± 2.8 nm for 
68
Ga-NRM (PDI 0.23 ± 0.02) and 15.5 ± 1.7 nm 
for 
68
Ga-NRM-TZ (PDI 0.26 ± 0.04). Reproducibility was remarkable, with mean 
hydrodynamic size showing a very narrow distribution over five independent syntheses 
(Figure 2h). STEM-HAADF analysis determined a mean core size of 2.9 ± 0.9 nm for 
68
Ga-NRM (Figure 2i) and 2.8 ± 0.6 nm for 
68
Ga-NRM -TZ (Figure 2j, Figure S4). The 
size analyses thus show that, under the selected conditions, TZ conjugation does not 
alter the size, shape, or aggregation state of the citrate-coated nano-radiomaterial. The 
difference between core size and hydrodynamic size is due to the very thick organic 
coating in both samples (Figure S5 in the ESM).  
A key feature of this 
68
Ga-NRM is its simultaneous provision of hot spot (positive) 
signals for PET and MRI. To confirm conservation of this property after TZ 
conjugation, we measured the relaxivity values for 
68
Ga-NRM and 
68
Ga-NRM-TZ at 
37ºC and a 1.5 T field strength (Figure 2k). Functionalization with TZ did not alter 
relaxometric behavior of 
68
Ga-NRM. 
68
Ga-NRM-TZ had a large r1 value of 7.1 mM
-1
·s
-
1
. This figure is larger than those for the clinically approved Gd-based complexes 
Magnevist© and Omniscan©, which have r1 values of 4.1 mM
-1
·s
-1
 at 1.5 T and 3.9 
mM
-1
·s
-1
 at 1.0 T, respectively. The relaxivity value for 
68
Ga-NRM-TZ results in a very 
low r2/r1 ratio of 2.5 that underlies the positive contrast ability of this bioorthogonal 
68
Ga-NRM. This was confirmed with phantom images of 
68
Ga-NRM-TZ, showing a 
clearly increased positive contrast in MRI and a simultaneous increase in the PET signal 
due to the core-doped 
68
Ga (Figure 2l).  
To study the 
68
Ga-NRM-TZ–trans-cyclooctene reaction kinetics, we reacted 68Ga-
NRM-TZ with different amounts of fluorescent TCO-Cy5 and calculated the pseudo 
first order rate constant (Figure 2m). As expected, the plots reveal fast reaction rates, 
with reactions completed within 15 to 20 minutes. Plotting these constants against the 
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molar concentration and linear fitting of the slope revealed a second order rate constant 
of 301 ± 27 M
-1
·s
-1
 (Figure S6 in the ESM). This value is in the normal range for an 
inverse demand Diels-Alder reaction and should guarantee a sufficiently fast reaction 
for in vivo imaging.
34
 
We studied the specificity of our Ab-TCO and demonstrated the bioorthogonal reaction 
in vitro by using commercial oxidized phospholipid snoopers. These consist of 12 
different lipid species spotted individually on a paper support, each spot containing 1 µg 
of the pure lipid.
35
 E06 antibody recognizes only the phosphocholine headgroup of 
oxidized phospholipid that is present in oxidized LDL, oxPAPC in the snooper. 
Therefore, if our Ab-TCO had the same reactivity as E06 we should only observe signal 
in the spot corresponding to that antigen (oxPAPC). We first incubated the snooper with 
the Ab-TCO, after that, we washed it and further incubated with our NRM-TZ. If the 
bioorthogonal reaction was happening we should detect the correct spot (oxPAPC) but 
because of the iron oxide accumulation. Results (Figure S7) confirm both the expected 
specificity of the antibody, there is only signal at the oxPAPC spot; and the selective 
reaction with the NRM-TZ, there is no accumulation of nanoparticles anywhere else. 
Because of the iron oxide nanoparticles color the accumulation can be directly observed 
by naked eye. 
Biodistribution, clearance and in vivo toxicity. 
We studied the biodistribution, clearance and in vivo toxicity of the probe, 
68
Ga-NRM-
TZ in the same conditions designed for the in vivo imaging experiments. The 
68
Ga-
NRM-TZ (1.7 nmol TZ, 12 MBq, 1.4 mg Fe/mL) was intravenously injected in ApoE
-/-
 
mice (42 weeks old, 25 weeks on a high fat diet; HFD). Ab-TCO (55 pmol) had been 
previously (24 h) injected. Three hours post-injection of 
68
Ga-NRM-TZ animals were 
sacrificed, organs harvested and the radioactive doses measured in a gammacounter. 
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Biodistribution results (Figure 3a) show a large accumulation in spleen and liver, typical 
of these NRM and of nanoparticles with this size 
18
. Importantly, the percentage of dose 
is very large in the aorta, almost the same as in the liver, suggesting a successful 
accumulation with the pretargeted approach. The rest of the organs show very low 
levels of radioactivity, as expected.  
For the clearance studies the same conditions were followed but including two groups 
of ApoE
-/-
 mice (42 weeks old, 25 weeks on a high fat diet; HFD) for comparison. In 
both groups, we injected the 
68
Ga-NRM-TZ (1.7 nmol TZ, 12 MBq, 1.4 mg Fe/mL). To 
the first group Ab-TCO (55 pmol) had been injected, 24 h before, while the second 
group was free of antibody. This way we could investigate if the pretargeted approach 
had any effect on the clearance of the NRM from the animals. Dynamic PET was used 
to monitor the activity in the whole body at different time points; 11 time points, from 5 
min to 90 min. Results, reported as mean standardized uptake values (SUV), show 
clearance from circulation (Figure 3b) and concomitant accumulation in liver (Figure 
3c), spleen (Figure 3d) and, to a lesser extent, in the bladder (Figure 3e) after 
approximately 60 minutes of injection of NRM. Clearly there is no difference between 
the two groups of animals, i.e. the injection of the Ab-TCO does not change the 
clearance profile of the NRM. 
The long-term in vivo effects of the 
68
Ga-NRM-TZ injection was studied in ApoE
-/-
 
mice. The serum levels for iron, total iron binding capacity (TIBC), alanine 
aminotransferase (ALT), aspartate aminotransferase (ALT) and alkaline phosphatase 
(AKP) were monitored 1 day, 3 days, 10 days and 18 days post-injection of the NRM or 
saline as control. As figure 4a shows, iron levels in serum don’t change in comparison 
to baseline values or saline injection. This is most likely due to the low concentration of 
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iron injected and its rapid elimination. Since the most important elimination organ is the 
liver we focused in the analysis of several indicators of liver function. 
TIBC represent the amount of iron that would be present in circulation should all the 
transferrin be saturated. Since transferrin is produced in the liver, TIBC is used as an 
indirect measurement of liver function. Similarly to iron levels, TIBC does not change 
compared to saline injection or baseline levels (Figure 4b). To complete the assessment 
of liver function after the injection of the NRM, the levels of ALT, AST and AKP were 
measured. In the case of ALT (Figure 4c) and AST (Figure 4d) the values slightly 
increase 10 days after the injection, both for saline and NRM injections, discarding any 
deleterious effect by the NRM. This change is normal considering that liver function in 
ApoE
-/-
 mice is affected. In fact, ApoE
-/-
 are considered also a model for non-alcoholic 
steatohepatitis.
36,37
 Finally, data for AKP don’t show any difference between the 
injection of our NRM or saline (Figure 4e). Altogether, clearance and toxicity data 
indicate that the two steps protocol does not affect the normal clearance of the probe, 
the typical for nanoparticles this size. Furthermore, the injection of the 
68
Ga-NRM-TZ 
does not elicit any deleterious effect in the animals, even considering that the main 
accumulation organ is the liver and that ApoE
-/-
 can suffer from altered liver function. 
Pretargeted hybrid detection of atherosclerosis. 
Having completed the characterization of the Ab-TCO and 
68
Ga-NRM-TZ components 
of the pretargeted approach, we proceeded to the in vivo imaging, using the strategy 
depicted in Figure 1c. In order to have a complete study we used the following 5 
different conditions (Figure 5): 
a) Full pretargeted approach (55 pmol of Ab-TCO + 68Ga-NRM-TZ) on 
atherosclerotic mice on high fat diet (42 weeks old, 25 weeks on a high fat diet, 
ApoE
-/-HFD
) 
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b) Full pretargeted approach on control C57BL/6 mice (42 weeks old). 
c) Full pretargeted approach on ApoE-/- in normal (chow) diet (42 weeks old, 
ApoE
-/-chow
). 
d) Pretargeted approach using control particles (68Ga-NRM) without tetrazine on 
ApoE
-/-HFD
  
e) Blocking experiment where, prior to the full pretargeted approach (55 pmol of 
Ab-TCO + 
68
Ga-NRM-TZ), the Ab was intravenously injected to block most of 
the recognition sites. 
Figure 5 shows a summary of the main findings after the PET/CT on these 5 conditions. 
Axial PET/CT images are all from the same anatomical region, the aortic arch (see also 
Figure S8 in the ESM). For condition a) PET/CT imaging of ApoE
-/-
 mice 1 hour after 
68
Ga-NRM-TZ injection revealed the unambiguous specific localization in several 
consecutive planes of the aortic arch (Figure 5a). In contrast, post 
68
Ga-NRM-TZ 
injection images from control C57BL/6 and ApoE 
-/-chow
 mice showed no noticeable 
signal in the aortic arch or whole aorta (Fig 5b and 5c). For condition d) PET/CT signal 
was also absented from ApoE
-/-HFD
 mice injected with unmodified 
68
Ga-NRM (Figure 
5d). Finally, in the blocking experiment, condition e), no signal was found. 
Nano-radiomaterial biodistribution was studied with a gammacounter after the imaging 
experiment (Figure S9). Analysis of radioactivity in the aorta revealed a remarkably 
large uptake in ApoE
-/-HFD
 mice (14.7 ± 2.7 %ID/g, N=4) compared to control 
conditions; b) 3.4 ± 1.5 %ID/g, N=3; c) 1.5 ± 0.5 %ID/g, N=3; d) 1.5 ± 0.3 %ID/g, N=3 
and e) 2.0 ± 0.8 %ID/g, N=5. 
These measurements confirm the clear uptake observed in the imaging experiments. It is 
especially noticeable the very large accumulation of signal in the pretargeted approach 
with an outstaning 14.7 % ID/g, confirming the specific accumulation of 
68
Ga-NRM-TZ 
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due to the bioorthogonal reaction with E06-TCO antibody. Furthermore, the results for 
two of the control conditions are particularly important since they demonstrate that the 
large uptake in the aorta (in condition a) is due to the specificity of the biorthogonal 
reaction (no uptake in condition d) and the selective recognition of oxidized 
phospholipids by the antibody (no uptake in the blocking experiment, condition e). 
This clear in vivo signal is remarkable considering the small amount of injected Ab-
TCO, providing clear evidence of the potential of this pretargeted approach with 
modified 
68
Ga-NRM. The good relaxometric values of 
68
Ga-NRM-TZ prompted us to 
check the ability of MRI to detect particle accumulation in the aorta. Given the poor 
sensitivity of MRI, monitoring the localization of iron oxide nanoparticles using their T1 
properties is non-trivial, especially at high magnetic fields. We recently demonstrated 
the feasibility of this approach,
17
 but in the present study we needed to take into account 
the extremely low concentration range used. Because of this limitation, we investigated 
the potential of MRI by ex vivo analysis of aortas from ApoE
-/-
 mice injected with 
68
Ga-
NRM or 
68
Ga-NRM-TZ (Figure 6). We performed a double-blind experiment in which 
the researchers injecting the tracers and extracting aortas were not involved in MRI 
acquisition and data analysis, and researchers analyzing the data didn’t know a priori 
which animals were control or experimental. This approach allowed us to successfully 
distinguish between animals injected with 
68
Ga-NRM and those injected with 
68
Ga-
NRM-TZ solely on the basis of imaging results. Clear hyperintense areas were evident 
in lesions, both in the axial view and in the 3D representation of the aorta (Figure 6c). 
Pseudocolored images show clear hypertintense areas in the lesion after the injection of 
68
Ga-NRM-TZ. 
 
Discussion 
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The non-invasive diagnosis of atherosclerosis is a hot topic in nanomedicine and 
molecular imaging. Although many imaging probes have been studied, it is not easy to 
find one providing clear in vivo detection. Among the many targets present in the 
disease we focused in oxidized phospholipids, key compounds in the initiation and 
progression of atherosclerosis. In this study we have used combination of biorthogonal 
chemistry and nano-radiomaterials for the detection of the disease in animal models. 
The rationale of using pretargeted imaging is based on three factors: the use of short 
half-life radioisotopes, the higher selectivity of the radiotracer, thus avoiding healthy 
tissue, and the rapid excretion of the radiotracer.
21
 With this aim we functionalized a 
commercially available antibody with TCO by amide formation. Quantification of this 
group showed and optimal value of 48 TCO molecules per IgM. The second component 
of the pretargeted imaging studied consisted on our 
68
Ga core-doped iron oxide 
nanoparticles, functionalized with TZ and, this way, ready for the biorthogonal reaction 
with the modified antibody. These NRM present excellent colloidal stability, stable 
radiolabeling and provide good T1-based signal in MRI as we have shown. Compared 
with traditional pretargeted imaging, the most remarkable features of our approach are 
the use of short half-life radioisotopes, the unambiguous detection of atherosclerosis 
with picomolar concentrations of the Ab and nanomolar concentrations of the NRM, 
and the use of hybrid PET/MR imaging to detect and structurally characterize the 
damaged tissue. These advances come at the cost of losing the rapid tracer excretion due 
to the size of the nanomaterial; however, this cost is more than compensated by the 
advantages, particularly in such a difficult field as atherosclerosis imaging. Proof of this 
is the important uptake detected in the aorta, with values difficult to see in the literature, 
key to this unambiguous detection of atherosclerosis. Furthermore, the large specific 
surface of these NRM makes them amenable to the incorporation of new moieties, 
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permitting new approaches, especially for therapy. The production of a new kind of 
bioorthogonal nano-radiomaterials through the synergistic combination of 
nanotechnology and radiochemistry shows for the first time that the range of 
applications of pretargeted imaging can be expanded to cardiovascular diseases and 
other in vivo imaging applications. 
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Figure 1. The approach followed in this study. a) IgM 3D structure and the conjugation of TCO 
molecules targeting primary amino groups in lysines (highlighted in blue in the structure, not to 
scale); b) Synthesis of 
68
Ga core-doped iron oxide nano-radiomaterials (NRM) and their 
functionalization with a tetrazine derivative compound. c) Imaging protocol. Mice received 
injections of Ab-TCO followed 24 hours later by injection of 
68
Ga-NRM-TZ. After 1 hour, in 
vivo PET scans were recorded of atherosclerotic lesions, and aortas were then excised and 
examined by ex vivo T1-MRI to detect localized regions of NRM accumulation. 
 
 
 
 
 
 
 
Figure 2. a) Fluorescence spectrum of Ab-TCO after bioorthogonal reaction with TZ-Cy3. b) 
gel filtration radio-chromatogram of the synthesized 68Ga-NRM; c) percentage of the total 
activity measured in the particles and the filtrate after incubation with mouse serum at 37 ºC for 
45 minutes, for 68Ga-NRM and 68Ga-NRM-TZ after ultracentrifugation; d) FTIR spectra for 
68Ga-NRM and 68Ga-NRM-TZ; e) zeta potential values for 68Ga-NRM and 68Ga-NRM-TZ 
(statistical analysis by two-tailed t-test, error bars indicate s.d., N = 3; *, P 0.0138). f) 
fluorescence spectrum of 68Ga-NRM-TZ before and after bioorthogonal reaction with TCO-
Cy5; g) quantification of TZ molecules in 68Ga-NRM-TZ versus the initial amount of 
benzylamino-tetrazine in the reaction with citrate molecules; h) hydrodynamic size values for 
five independent syntheses of 68Ga-NRM and 68Ga-NRM-TZ; scatter dot plot with 95% CI. i) 
STEM-HAADF for 68Ga-NRM; scale bar, 50 nm. j) STEM-HAADF for 68Ga-NRM -TZ; scale 
bar, 20 nm. k) relaxivity values (r1, r2 and r2/r1) for 
68Ga-NRM and 68Ga-NRM-TZ. l) image 
phantoms obtained at different iron concentrations of 68Ga-NRM-TZ by MRI (top row) and PET 
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(bottom row) and m) reaction rates for 68Ga-NRM-TZ cycloaddition to different concentrations 
of TCO-Cy5. 
 
 
 
 
 
 
Figure 3. a) 68Ga-NRM-TZ organ biodistribution expressed as the percentage injected dose per 
gram (%ID/g) in ApoE-/- mice (24 h before Ab-TCO was injected, N=5). Standardized uptake 
values from dynamic PET up to 120 minutes post-injection of 68Ga-NRM-TZ in b) heart; c) 
liver; d) spleen and e) bladder (N=3). 
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Figure 4. Serum levels in ApoE-/- mice after the injection of saline (N = 2) or 68Ga-NRM-TZ (N 
= 4) for: a) iron; b) total iron binding capacity; c) alanine aminotransferase; d) aspartate 
aminotransferase and e) alkaline phosphatase. Dotted line indicates baseline levels. 
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Figure 5. a-e), Axial PET/CT images taken 24 h post-injection of Ab-TCO and 1 h post-
injection of nano-radiotracer: a, ApoE
-/-HFD
 mice injected with 
68
Ga-NRM-TZ; b, C57BL/6 mice 
injected with 
68
Ga-NRM-TZ; c, ApoE
-/-chow
 mice injected with 
68
Ga-NRM-TZ; d, ApoE
-/-HFD
 
mice injected with 
68
Ga-NRM and e, ApoE
-/-HFD
 mice injected with Ab, prior to Ab-TCO, and 
68
Ga-NRM-TZ. f) Radioactivity uptake in mice aortas for the five conditions, detected with a 
gamma counter 2 h post-injection and expressed as the % of injected dose per gram of tissue 
(mean ± standard deviation; statistical analysis by two-tailed t-test, N = 3-5; ****, P 0.0009). 
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Figure 6. a) schematic representation of the ex vivo MR images; Axial magnetic resonance 
(pseudo-colored and normal contrast) and 3D MRP images from ApoE
-/-HFD
 mice 24 h post-
injection of Ab-TCO and 1 h post-injection of b), 
68
Ga-NRM and c), 
68
Ga-NRM-TZ. 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 28 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 29 
 
 
 
 
 
Unambiguous detection of atherosclerosis by the in vivo reaction of 68Ga iron oxide nanoparticles with 
anti-oxidized phospholipids antibody 
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